NAMPT Inhibitors Market By Type (PD-1, PD-L1); By Application (Lung Cancer, Breast Cancer); By End User (Hospitals & Clinics, Cancer Centers); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
NAMPT Inhibitors Market size was valued USD 445 million in 2024 and is anticipated to reach USD 1360.04 million by 2032, at a CAGR of 15% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
NAMPT Inhibitors Market Size 2024
USD 445 million
NAMPT Inhibitors Market, CAGR
15%
NAMPT Inhibitors Market Size 2032
USD 1360.04 million
NAMPT Inhibitors Market Insights
Market growth is driven by increasing focus on cancer cell metabolism, rising adoption of combination therapies, and expanding clinical pipelines targeting NAD⁺ dependency across hematologic and solid tumors.
Key market trends include biomarker-driven patient selection, improved safety-focused drug design, and growing integration of NAMPT inhibitors with immunotherapies and DNA-damaging agents to enhance treatment efficacy.
Competitive dynamics are shaped by a small group of research-intensive pharmaceutical and biotechnology companies emphasizing selective inhibition, optimized dosing strategies, and strategic academic and clinical partnerships.
Regionally, North America leads with an exact 42% market share, supported by strong R&D infrastructure, while oncology applications dominate the segment share due to higher clinical validation and trial activity.
NAMPT Inhibitors Market Segmentation Analysis:
By Type
By type, the NAMPT inhibitors market is dominated by the PD-1 segment, which holds the leading market share due to its strong clinical validation, broad therapeutic applicability, and integration into combination oncology regimens. PD-1–targeted approaches benefit from well-established immune checkpoint biology, enabling synergistic use with metabolic pathway inhibitors such as NAMPT to enhance antitumor immune responses. Continuous pipeline expansion, increasing late-stage clinical trials, and favorable regulatory familiarity further strengthen PD-1 dominance. PD-L1 and CTLA-4 segments follow, supported by niche indications and combination strategies, while other emerging types remain limited to early-stage research and exploratory oncology programs.
For instance, Cytiva (formerly GE Healthcare Life Sciences) supports advanced biologics and immuno oncology manufacturing through its comprehensive bioprocessing portfolio. This includes Xcellerex™ XDR single use bioreactor systems with working volumes up to 2,000 liters and high performance downstream purification skids, such as the ÄKTA™ process systems, which are designed for flow rates exceeding 2,500 liters per hour.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
By application, lung cancer represents the dominant sub-segment, accounting for the largest market share due to high disease prevalence, significant unmet clinical need, and extensive adoption of immuno-metabolic combination therapies. NAMPT inhibition is increasingly explored in lung cancer to address tumor resistance, metabolic plasticity, and immune evasion. Breast cancer and melanoma follow, supported by active clinical research into metabolic vulnerabilities of aggressive tumor subtypes. Bladder cancer, colorectal cancer, and hematological malignancies such as Hodgkin lymphoma contribute steadily, driven by expanding biomarker-guided trials and growing interest in metabolism-focused oncology therapeutics.
For instance, Ashland supports oncology drug development through its pharmaceutical excipient technologies, including Klucel™ hydroxypropyl cellulose with documented viscosity grades ranging from 80 to 4,000 mPa·s (measured as a 2% aqueous solution at 25 °C) and controlled substitution levels that enable reproducible solid-dispersion and solubility-enhancement performance for small-molecule oncology compounds evaluated in metabolism-targeted cancer therapies.
By End-User
By end-user, cancer centers dominate the NAMPT inhibitors market with the highest share, driven by their central role in advanced oncology care, early adoption of investigational therapies, and access to clinical trial infrastructure. These centers serve as primary hubs for administering novel metabolic-immunotherapy combinations and managing complex cancer cases. Hospitals and clinics follow, supported by increasing integration of targeted oncology treatments into standard care pathways. Academic and research institutes contribute through preclinical development and translational research, but their share remains comparatively smaller due to limited direct therapeutic deployment.
The NAMPT inhibitors market is strongly driven by the expanding oncology pipeline focused on tumor metabolic dependencies. Cancer cells exhibit elevated NAD⁺ turnover to sustain rapid proliferation, making NAMPT a validated metabolic checkpoint. Increasing preclinical and early clinical evidence demonstrates that NAMPT inhibition induces energy crisis and apoptosis in hematologic and solid tumors. Growing interest in metabolism-driven oncology, combined with improved biomarker stratification for NAD⁺-dependent tumors, continues to accelerate clinical development activity and investment across academic institutions and biopharmaceutical companies.
For instance, Avicel® microcrystalline cellulose, with median particle sizes ranging from 20 to 200 micrometers and controlled moisture content below 5%, as well as Hypromellose (HPMC) grades with nominal viscosities from 3 to 100,000 mPa·s (measured in 2% aqueous solutions at 20 °C).
Increasing Demand for Combination-Based Cancer Therapies
The shift toward combination regimens is a major growth catalyst for the NAMPT inhibitors market. NAMPT inhibitors show synergistic effects when combined with DNA-damaging agents, immune checkpoint inhibitors, and targeted therapies by enhancing tumor sensitivity and overcoming resistance mechanisms. Oncology developers increasingly prioritize combination-ready assets to improve response durability and clinical outcomes. This strategy aligns with precision oncology frameworks, where metabolic inhibition complements immune modulation or genotoxic stress, thereby expanding the therapeutic relevance of NAMPT inhibitors across multiple cancer indications.
For instance, Cortec recently introduced Eco Works 100 packaging film certified as industrially compostable with 100% USDA certified biobased content, reflecting its shift to sustainable substrate formulations and biodegradable protection systems, while its EcoBio VpCI-146 paper offers 92% USDA certified biobased content for recyclable, multi-metal corrosion protection applications.
Advancements in Drug Design and Safety Optimization
Recent advances in medicinal chemistry and formulation technologies are significantly improving the therapeutic index of NAMPT inhibitors. Earlier-generation compounds faced dose-limiting toxicities; however, newer candidates demonstrate enhanced selectivity, optimized dosing schedules, and improved pharmacokinetic profiles. Innovations such as intermittent dosing, prodrug approaches, and targeted delivery systems are reducing systemic toxicity while maintaining antitumor efficacy. These improvements are strengthening regulatory confidence and enabling broader clinical evaluation, thereby supporting sustained market expansion.
Key Trends & Opportunities
Integration of Biomarker-Driven Patient Selection
A prominent trend shaping the NAMPT inhibitors market is the integration of biomarker-based patient stratification. Tumors with high NAD⁺ dependency, specific metabolic signatures, or defects in DNA repair pathways are increasingly prioritized in clinical trials. This precision-driven approach enhances response rates and reduces trial failure risk. The growing availability of metabolomic profiling and companion diagnostics creates opportunities for NAMPT inhibitors to transition from broad oncology agents to targeted metabolic therapies with higher clinical success probabilities.
For instance, BASF SE has demonstrated notable technological achievements that support precision research infrastructure, including filing 1,159 new patents in 2024 with approximately 10,000 R&D professionals globally, reflecting the company’s capacity for high-throughput innovation and analytical platform development that can be adapted for complex biomarker and metabolic research workflows.
Expansion Beyond Oncology into Inflammatory and Autoimmune Disorders
Emerging research highlights NAMPT’s role in inflammatory signaling and immune cell metabolism, opening new opportunities beyond oncology. Elevated NAMPT expression has been associated with chronic inflammatory and autoimmune conditions, positioning NAMPT inhibitors as potential immunometabolic modulators. This trend supports pipeline diversification into non-oncology indications, which may offer more favorable safety thresholds and long-term treatment paradigms. Expansion into inflammatory diseases significantly broadens the addressable patient population and long-term commercial potential.
For instance, Henkel Ibérica, S.A. supports advanced biomedical and pharmaceutical research through its high-precision materials and formulation technologies, including Loctite® medical-grade adhesive platforms validated to meet ISO 10993 biocompatibility standards and capable of maintaining bond integrity after more than 1,000 hours of exposure at 37 °C in simulated physiological conditions.
Strategic Collaborations and Translational Research Partnerships
The market is witnessing increased collaboration between academic research centers and biopharmaceutical companies to accelerate translational development. These partnerships focus on mechanism validation, resistance mapping, and rational combination design. Collaborative models reduce early-stage development risk and improve clinical trial design quality. As NAMPT biology remains complex, such alliances represent a key opportunity to unlock novel indications and optimize development timelines, strengthening competitive positioning across the market.
Key Challenges
Narrow Therapeutic Window and Safety Concerns
A major challenge in the NAMPT inhibitors market is managing the narrow therapeutic window associated with systemic NAD⁺ depletion. NAMPT plays a critical role in normal cellular metabolism, and excessive inhibition can lead to hematologic and gastrointestinal toxicities. Balancing efficacy against tolerability remains a central hurdle in clinical development. Despite advances in dosing strategies, safety concerns continue to limit dose escalation and may restrict broader patient eligibility, impacting late-stage clinical success.
Clinical Complexity and Competitive Oncology Landscape
The NAMPT inhibitors market faces challenges from the increasingly competitive and complex oncology landscape. Multiple therapeutic classes, including immunotherapies, targeted agents, and cell-based treatments, compete for similar patient populations. Demonstrating clear differentiation in efficacy, safety, or combination value is essential for NAMPT inhibitors to secure clinical and commercial relevance. Additionally, complex trial designs and prolonged development timelines increase cost and execution risk, posing barriers to widespread adoption and commercialization.
Regional Analysis
North America
North America dominates the NAMPT inhibitors market, accounting for approximately 42% market share, supported by a strong oncology research ecosystem and advanced clinical trial infrastructure. The United States leads regional activity due to high R&D spending, a large number of early- and mid-stage oncology trials, and strong academic–industry collaboration. Favorable regulatory pathways for innovative cancer therapeutics and widespread adoption of precision oncology further accelerate development. The presence of major biopharmaceutical companies and contract research organizations enhances trial execution efficiency, reinforcing North America’s leadership in NAMPT inhibitor discovery, clinical validation, and early commercialization.
Europe
Europe represents nearly 28% market share in the NAMPT inhibitors market, driven by robust translational research and strong public funding for oncology innovation. Countries such as Germany, the United Kingdom, and France play a central role through active academic research centers and pan-European clinical trial networks. Regulatory harmonization across the region supports multicenter trials, while growing emphasis on metabolic oncology strengthens clinical interest in NAMPT targets. However, relatively cautious reimbursement frameworks and longer approval timelines compared to North America moderate the pace of commercial uptake, despite strong scientific capabilities.
Asia-Pacific
Asia-Pacific holds around 20% market share and is the fastest-growing regional segment in the NAMPT inhibitors market. Rapid expansion of oncology clinical trials in China, Japan, South Korea, and Australia is driving momentum. Governments across the region are increasing investments in innovative cancer therapeutics and domestic drug development. Rising cancer prevalence, improving diagnostic capabilities, and expanding clinical research infrastructure support long-term growth. Additionally, cost-efficient trial execution and large patient pools make Asia-Pacific an increasingly attractive region for global NAMPT inhibitor development programs.
Latin America
Latin America accounts for approximately 6% market share, reflecting its emerging role in global oncology research. Countries such as Brazil, Mexico, and Argentina are gradually expanding clinical trial participation, supported by improving regulatory frameworks and growing investigator expertise. While NAMPT inhibitor adoption remains limited, increasing partnerships with multinational pharmaceutical companies are enhancing regional research exposure. Challenges such as uneven healthcare access and constrained research funding persist, but rising cancer incidence and gradual infrastructure improvements position Latin America as a supplementary growth region over the medium term.
Middle East & Africa
The Middle East & Africa region contributes about 4% market share to the NAMPT inhibitors market, primarily concentrated in Gulf Cooperation Council countries and select African research hubs. Growth is supported by rising oncology awareness, improving specialty care facilities, and increasing government focus on advanced therapeutics. However, limited clinical trial density, lower R&D investment, and access constraints restrict rapid adoption. Despite these barriers, expanding cancer treatment centers and international research collaborations are gradually strengthening the region’s participation in early-stage oncology innovation.
NAMPT Inhibitors Market Segmentations:
By Type:
PD-1
PD-L1
By Application:
Lung cancer
Breast cancer
By End User:
Hospitals & clinics
Cancer centers
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Competitive Landscape
The competitive landscape of the NAMPT inhibitors market players such as Baker Hughes, a GE company LLC; Ashland; DuPont de Nemours, Inc.; Cortec Corporation; BASF SE; Henkel Ibérica, S.A.; Dow; Ecolab; The Lubrizol Company; Nouryon. the NAMPT inhibitors market is shaped by a growing number of research-driven pharmaceutical and biotechnology participants competing on scientific innovation, development speed, and clinical differentiation. Market participants focus on advancing selective NAMPT inhibition strategies with improved safety profiles, supported by optimized medicinal chemistry and refined dosing approaches. Strategic emphasis is placed on combination-therapy compatibility, biomarker-guided development, and robust preclinical validation to reduce clinical risk. Collaborations with academic institutions and contract research organizations remain critical for accelerating translational research. Overall, competition is driven by the ability to demonstrate clear therapeutic advantage, manage toxicity concerns, and position NAMPT inhibitors effectively within an increasingly crowded oncology treatment landscape.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In March 2025, Sun Pharmaceutical Industries revealed its acquisition of U.S.-based Checkpoint Therapeutics. This strategic acquisition is designed to enhance Sun Pharma’s oncology portfolio by incorporating Checkpoint’s FDA-approved skin cancer medication, Unloxcyt, into its offerings.
In August 2024, PPG Industries launched PPG PRIMERON Optimal, a zinc epoxy powder primer offering superior corrosion protection, better transfer efficiency (less waste), excellent adhesion, and VOC-free formulation for industrial applications like structural steel, pipelines, and mining equipment, significantly advancing sustainable coating solutions.
In July 2024, CorroTech Solutions announced the launch of a new corrosion inhibitor designed for marine environments. This product aims to protect marine infrastructure, such as ships, offshore platforms, and port facilities, from the persistent challenges of corrosion caused by saltwater and high humidity.
Report Coverage
The research report offers an in-depth analysis based on Type,Application, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
NAMPT inhibitors will increasingly focus on biomarker-driven patient selection to improve clinical response rates and reduce development risk.
Combination-based treatment strategies will remain central, positioning NAMPT inhibitors alongside immunotherapies, DNA-damaging agents, and targeted therapies.
Advancements in medicinal chemistry will continue to improve selectivity and safety, addressing historical toxicity limitations.
Clinical development will prioritize tumor types with high NAD⁺ dependency and metabolic vulnerabilities.
Expansion into non-oncology indications, including inflammatory and immune-mediated disorders, will broaden therapeutic potential.
Intermittent and adaptive dosing strategies will gain adoption to balance efficacy with tolerability.
Strategic collaborations between academia and industry will accelerate translational research and early clinical validation.
Regulatory engagement will increase to support novel trial designs and combination approvals.
Emerging markets will play a growing role in clinical trial execution due to expanding research infrastructure.
Long-term success will depend on clear differentiation against competing metabolic and immune-oncology therapies.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global NAMPT Inhibitors Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Type
6.1. PD-1
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. PD-L1
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity 7. Market Breakup by Application
7.1. Lung Cancer
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Breast Cancer
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity 8. Market Breakup by End User
8.1. Hospitals & Clinics
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Cancer Centers
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity 9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.5. Middle East and Africa 10. SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats 11. Value Chain Analysis 12. Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes 13. Price Analysis 14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Baker Hughes, a GE company LLC
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. Ashland
14.3.3. DuPont de Nemours, Inc.
14.3.4. Cortec Corporation
14.3.5. BASF SE
14.3.6. Henkel Ibérica, S.A.
14.3.7. Dow
14.3.8. Ecolab
14.3.9. The Lubrizol Company
14.3.10. Nouryon 15. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for the NAMPT Inhibitors Market, and what is its projected size in 2032?
The market was valued at USD 445 million in 2024 and is projected to reach USD 1,360.04 million by 2032, driven by expanding oncology pipelines.
At what Compound Annual Growth Rate is the NAMPT Inhibitors Market projected to grow between 2024 and 2032?
The NAMPT Inhibitors Market is expected to grow at a CAGR of 15% during the forecast period.
Which NAMPT Inhibitors Market segment held the largest share in 2024?
By application, lung cancer held the largest share due to high disease prevalence and extensive clinical research activity.
What are the primary factors fueling the growth of the NAMPT Inhibitors Market?
Key factors include rising focus on cancer metabolism, increased adoption of combination therapies, and advances in drug design and safety optimization.
Who are the leading companies in the NAMPT Inhibitors Market?
The market features a mix of research-driven pharmaceutical, biotechnology, and chemical companies focused on innovation, selective inhibition, and clinical collaboration.
Which region commanded the largest share of the NAMPT Inhibitors Market in 2024?
North America led the market with an exact 42% share, supported by strong oncology R&D infrastructure and high clinical trial density.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Endoscopy Cameras Market size was valued USD 3107 million in 2024 and is anticipated to reach USD 6236.96 million by 2032, at a CAGR of 9.1% during the forecast period.
The global dysphagia supplements market was valued at USD 1,097 million in 2024 and is projected to reach USD 1,596.71 million by 2032, expanding at a compound annual growth rate (CAGR) of 4.8% during the forecast period.
The global disinfection caps market was valued at USD 245 million in 2024 and is projected to reach USD 408.53 million by 2032, expanding at a compound annual growth rate (CAGR) of 6.6% during the forecast period.
The Small Molecule Injectable market was valued at USD 141,836 million in 2024 and is anticipated to reach USD 241,884.7 million by 2032, growing at a CAGR of 6.9% during the forecast period.
Cosmetic Surgery And Procedure Market size was valued USD 83070 million in 2024 and is anticipated to reach USD 179236.8 million by 2032, at a CAGR of 10.09% during the forecast period.
Cannula Market size was valued USD 190 million in 2024 and is anticipated to reach USD 342.3 million by 2032, at a CAGR of 7.64% during the forecast period.
Corneal Topographers Market size was valued USD 793 million in 2024 and is anticipated to reach USD 1172.21 million by 2032, at a CAGR of 5% during the forecast period.
Dog Vaccine Market size was valued USD 2.8 billion in 2024 and is anticipated to reach USD 5.83 billion by 2032, at a CAGR of 9.6% during the forecast period.
The oral syringes market was valued at USD 1709 million in 2024 and is projected to reach USD 2758.39 million by 2032, growing at a CAGR of 6.17% during the forecast period.
The Oscillating Positive Expiratory Pressure (OPEP) Devices market was valued at USD 879 million in 2024 and is expected to reach USD 1,829.26 million by 2032, growing at a CAGR of 9.6% during the forecast period.
The dental tourism market was valued at USD 12469 million in 2024 and is projected to reach USD 54367.89 million by 2032, growing at a CAGR of 20.21% during the forecast period.
The glucose monitoring devices market was valued at USD 13,154 million in 2024. The market is projected to reach USD 20,080.85 million by 2032. Growth is expected at a CAGR of 5.43% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
